- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07252739
Subestudio KEYMAKER-U01 01J: Un estudio de pembrolizumab más MK-1084 en participantes con cáncer de pulmón de células no pequeñas (CPCNP) con mutaciones del oncogén viral del sarcoma de rata Kirsten homólogo (KRAS) G12C (MK-3475-01J/KEYMAKER-U01J)
KEYMAKER-U01 Subestudio 01J: Un estudio paraguas aleatorizado de fase 2 con brazos rotatorios de agentes de investigación para el tratamiento de primera línea de participantes con cáncer de pulmón de células no pequeñas (CPCNP) no escamoso avanzado o metastásico con mutaciones KRAS G12C
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7560908
- Reclutamiento
- Centro de Oncología de Precisión ( Site 0160)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56991612199
-
Santiago, Region M. de Santiago, Chile, 7500921
- Reclutamiento
- Fundacion Arturo Lopez Perez ( Site 0167)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56224205098
-
Santiago, Region M. de Santiago, Chile, 8420383
- Reclutamiento
- Bradfordhill ( Site 0168)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56998744662
-
-
-
-
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Severance Hospital Yonsei University Health System ( Site 0080)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82222280880
-
-
-
-
-
Seville, España, 41009
- Reclutamiento
- Hospital Universitario Virgen de la Macarena ( Site 0093)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 671560092
-
-
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Reclutamiento
- Clermont Oncology Center ( Site 0041)
-
Contacto:
- Study Coordinator
- Número de teléfono: 386-538-3169
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58102
- Reclutamiento
- Sanford Health Roger Maris Cancer Center ( Site 0039)
-
Contacto:
- Study Coordinator
- Número de teléfono: 701-234-2000
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Reclutamiento
- Sanford Cancer Center Oncology Clinic ( Site 0038)
-
Contacto:
- Study Coordinator
- Número de teléfono: 605-328-8000
-
-
-
-
Northern Savonia
-
Kuopio, Northern Savonia, Finlandia, 70200
- Reclutamiento
- Kuopion Yliopistollinen Sairaala ( Site 0261)
-
Contacto:
- Study Coordinator
- Número de teléfono: +35817173311
-
-
Pohjanmaa
-
Vaasa, Pohjanmaa, Finlandia, 65130
- Reclutamiento
- Vaasan Keskussairaala ( Site 0263)
-
Contacto:
- Study Coordinator
- Número de teléfono: +358405533545
-
-
Southwest Finland
-
Turku, Southwest Finland, Finlandia, 20520
- Reclutamiento
- Turku University Hospital ( Site 0262)
-
Contacto:
- Study Coordinator
- Número de teléfono: +35823138709
-
-
Uusimaa
-
Helsinki, Uusimaa, Finlandia, 00290
- Reclutamiento
- HYKS Syöpätautien klinikka ( Site 0260)
-
Contacto:
- Study Coordinator
- Número de teléfono: +358406682951
-
-
-
-
Attica
-
Athens, Attica, Grecia, 106 76
- Reclutamiento
- Evangelismos General Hospital of Athens ( Site 0200)
-
Contacto:
- Study Coordinator
- Número de teléfono: +302132041631
-
-
-
-
-
Central, Hong Kong, 0000
- Reclutamiento
- Hong Kong Integrated Oncology Centre ( Site 0232)
-
Contacto:
- Study Coordinator
- Número de teléfono: +85237006888
-
Hong Kong, Hong Kong
- Reclutamiento
- Queen Mary Hospital ( Site 0230)
-
Contacto:
- Study Coordinator
- Número de teléfono: +85222551727
-
Kowloon, Hong Kong
- Reclutamiento
- Hong Kong United Oncology Centre ( Site 0231)
-
Contacto:
- Study Coordinator
- Número de teléfono: +852 2386 8002
-
-
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Reclutamiento
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00390223903829
-
-
-
-
Overijssel
-
Deventer, Overijssel, Países Bajos, 7416 SE
- Reclutamiento
- Deventer Ziekenhuis ( Site 0272)
-
Contacto:
- Study Coordinator
- Número de teléfono: +31570536437
-
-
South Holland
-
Leiden, South Holland, Países Bajos, 2333 ZA
- Reclutamiento
- Leids Universitair Medisch Centrum ( Site 0273)
-
Contacto:
- Study Coordinator
- Número de teléfono: +31715566376
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 02-781
- Reclutamiento
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
-
Contacto:
- Study Coordinator
- Número de teléfono: 48 22 546 23 36
-
-
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210000
- Reclutamiento
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
-
Contacto:
- Study Coordinator
- Número de teléfono: +8602568182222
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330209
- Reclutamiento
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
-
Contacto:
- Study Coordinator
- Número de teléfono: +86 791 8631 9333
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200032
- Reclutamiento
- Zhongshan Hospital Fudan University ( Site 0319)
-
Contacto:
- Study Coordinator
- Número de teléfono: +8615000229853
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana, 610066
- Reclutamiento
- West China Hospital, Sichuan University ( Site 0315)
-
Contacto:
- Study Coordinator
- Número de teléfono: +8618980602252
-
-
-
-
Bangkok
-
Bangkok, Bangkok, Tailandia, 10300
- Reclutamiento
- Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
-
Contacto:
- Study Coordinator
- Número de teléfono: +6622443461
-
Bangkok, Bangkok, Tailandia, 10700
- Reclutamiento
- Faculty of Medicine Siriraj Hospital ( Site 0350)
-
Contacto:
- Study Coordinator
- Número de teléfono: +6624194488-9
-
-
-
-
-
Adana, Turquía (Türkiye), 34010
- Reclutamiento
- Koç Üniversitesi Hastanesi ( Site 0142)
-
Contacto:
- Study Coordinator
- Número de teléfono: 08502508250-21251
-
Adana, Turquía (Türkiye), 1250
- Reclutamiento
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
-
Contacto:
- Study Coordinator
- Número de teléfono: +905537766235
-
Ankara, Turquía (Türkiye), 6230
- Reclutamiento
- Hacettepe Universite Hastaneleri ( Site 0140)
-
Contacto:
- Study Coordinator
- Número de teléfono: +90 312 305 50 00
-
Ankara, Turquía (Türkiye), 06680
- Reclutamiento
- Liv Hospital Ankara ( Site 0146)
-
Contacto:
- Study Coordinator
- Número de teléfono: 905469299990
-
-
Kayseri
-
Talas, Kayseri, Turquía (Türkiye), 38039
- Reclutamiento
- Erciyes University ( Site 0145)
-
Contacto:
- Study Coordinator
- Número de teléfono: 905366550924
-
-
-
-
-
Kyiv, Ucrania, 03022
- Activo, no reclutando
- VISION PARTNER Medical Centre ( Site 0135)
-
Kyiv, Ucrania, 03151
- Reclutamiento
- LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
-
Contacto:
- Study Coordinator
- Número de teléfono: +380671502987
-
-
Cherkasy Oblast
-
Cherkasy, Cherkasy Oblast, Ucrania, 18009
- Reclutamiento
- COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
-
Contacto:
- Study Coordinator
- Número de teléfono: +380472370123
-
-
Dnipropetrovsk Oblast
-
Kryvyi Rih, Dnipropetrovsk Oblast, Ucrania, 50000
- Reclutamiento
- Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
-
Contacto:
- Study Coordinator
- Número de teléfono: +380677490687
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ucrania, 76018
- Reclutamiento
- Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
-
Contacto:
- Study Coordinator
- Número de teléfono: 380978411455
-
-
Kirovohrad Oblast
-
Kropyvnytskyi, Kirovohrad Oblast, Ucrania, 25011
- Reclutamiento
- Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
-
Contacto:
- Study Coordinator
- Número de teléfono: +380958718674
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ucrania, 79059
- Reclutamiento
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
-
Contacto:
- Study Coordinator
- Número de teléfono: +380677724757
-
-
Vinnytsia Oblast
-
Vinnitsya, Vinnytsia Oblast, Ucrania, 21029
- Reclutamiento
- Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
-
Contacto:
- Study Coordinator
- Número de teléfono: 380953105783
-
-
Zakarpattia Oblast
-
Uzhhorod, Zakarpattia Oblast, Ucrania, 88000
- Reclutamiento
- Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
-
Contacto:
- Study Coordinator
- Número de teléfono: +380506847086
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
- Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
- Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
- Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected
- Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
- Has undetectable hepatitis C (HCV) viral load if HCV-infected
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
- Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
- Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
- Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
- Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
- Has received previous treatment with an agent targeting KRAS
- Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
- Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
- Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
- Has a history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A- Pembrolizumab + MK-1084
Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen. |
Oral Administration Intravenous administration
Otros nombres:
|
|
Experimental: Arm B- Pembrolizumab + MK-1084 + Cetuximab
Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m^2 every 2 weeks. |
Intravenous administration Oral Administration Intravenous administration
Otros nombres:
|
|
Experimental: Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)
Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks. |
Oral Administration Intravenous administration
Otros nombres:
Injection powder for intravenous infusion
Otros nombres:
Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 [Hl] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants with a Dose Limiting Toxicity (DLT)
Periodo de tiempo: Up to approximately 21 days
|
A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug. |
Up to approximately 21 days
|
|
Percentage of Participants who Experience at Least One Adverse Event (AE)
Periodo de tiempo: Up to approximately 84 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 84 months
|
|
Percentage of Participants who Discontinue Study Intervention Due to an AE
Periodo de tiempo: Up to approximately 84 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 84 months
|
|
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
Periodo de tiempo: Up to approximately 84 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to approximately 84 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
Periodo de tiempo: Up to approximately 84 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. |
Up to approximately 84 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR
Periodo de tiempo: Up to approximately 84 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 84 months
|
|
Overall Survival (OS)
Periodo de tiempo: Up to approximately 84 months
|
OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented. |
Up to approximately 84 months
|
|
Area Under the Concentration-Time Curve (AUC) for MK-1084
Periodo de tiempo: At designated timepoints (up to approximately 44 days)
|
Blood samples will be collected to determine the AUC of MK-1084. |
At designated timepoints (up to approximately 44 days)
|
|
Maximum Concentration (Cmax) of MK-1084
Periodo de tiempo: At designated timepoints (up to approximately 44 days)
|
Blood samples will be collected to estimate Cmax of MK-1084. |
At designated timepoints (up to approximately 44 days)
|
|
Trough Concentration (Ctrough) of MK-1084
Periodo de tiempo: At designated timepoints (up to approximately 84 months)
|
Blood samples will be collected to determine the Ctrough of MK-1084. |
At designated timepoints (up to approximately 84 months)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Enfermedad de Parkinson 4, cuerpo autosómico dominante de Lewy
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Cetuximab
- pembrolizumab
Otros números de identificación del estudio
- 3475-01J
- U1111-1321-3999 (Identificador de registro: UTN)
- 2025-521939-36-00 (Identificador de registro: EU CT)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .